MX387405B - Aptámeros específicos de tlr-4 y usos de los mismos. - Google Patents

Aptámeros específicos de tlr-4 y usos de los mismos.

Info

Publication number
MX387405B
MX387405B MX2016016992A MX2016016992A MX387405B MX 387405 B MX387405 B MX 387405B MX 2016016992 A MX2016016992 A MX 2016016992A MX 2016016992 A MX2016016992 A MX 2016016992A MX 387405 B MX387405 B MX 387405B
Authority
MX
Mexico
Prior art keywords
tlr
relates
aptamer
methods
increase
Prior art date
Application number
MX2016016992A
Other languages
English (en)
Other versions
MX2016016992A (es
Inventor
Yébenes Ana Moraga
Gómez-Chacón Gerónimo Fernández
Hernández Ignacio Lizasoain
Sánchez María Ángeles Moro
PALMA Mª ELENA MARTÍN
Muñoz Víctor Manuel González
Original Assignee
Aptatargets S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptatargets S L filed Critical Aptatargets S L
Publication of MX2016016992A publication Critical patent/MX2016016992A/es
Publication of MX387405B publication Critical patent/MX387405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)

Abstract

La presente invención se refiere a un aptámero de ácido nucleico con capacidad de unirse específicamente e inhibir TLR-4 caracterizado porque comprende una secuencia seleccionada del grupo que consiste en SEQ ID NO: 1 y SEQ ID NO: 2 o una variante funcionalmente equivalente de las mismas que tiene al menos 70 % de identidad de secuencia, con SEQ ID NO: 1 o SEQ ID NO: 2. un complejo que comprende el aptámero y un grupo funcional, una composición farmacéutica que contiene al aptámero o al complejo, segundo uso farmacéutico del complejo, uso in vitro del aptámero o complejo y métodos in vitro para detección o inhibición de TLR-4.
MX2016016992A 2014-06-24 2015-06-24 Aptámeros específicos de tlr-4 y usos de los mismos. MX387405B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430955A ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos
PCT/EP2015/064277 WO2015197706A1 (en) 2014-06-24 2015-06-24 Aptamers specific for tlr-4 and uses thereof

Publications (2)

Publication Number Publication Date
MX2016016992A MX2016016992A (es) 2017-05-03
MX387405B true MX387405B (es) 2025-03-18

Family

ID=53496661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016992A MX387405B (es) 2014-06-24 2015-06-24 Aptámeros específicos de tlr-4 y usos de los mismos.

Country Status (18)

Country Link
US (4) US10196642B2 (es)
EP (1) EP3161139B1 (es)
JP (2) JP6959738B2 (es)
KR (1) KR102454682B1 (es)
CN (2) CN106459980B (es)
AU (1) AU2015279248B2 (es)
BR (1) BR112016030172B1 (es)
CA (1) CA2953020C (es)
DK (1) DK3161139T3 (es)
ES (2) ES2555160B1 (es)
MA (1) MA40283A (es)
MX (1) MX387405B (es)
PL (1) PL3161139T3 (es)
PT (1) PT3161139T (es)
RU (1) RU2709718C9 (es)
SI (1) SI3161139T1 (es)
WO (1) WO2015197706A1 (es)
ZA (1) ZA201700363B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129462A1 (en) * 2014-04-07 2017-02-15 INSERM - Institut National de la Santé et de la Recherche Médicale New method for producing outer membrane vesicles
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
EP3494994A1 (en) * 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
EP3856904A2 (en) * 2018-09-28 2021-08-04 Augmanity Nano Ltd Methods and compositions for selection of functional aptamers
CA3110914A1 (en) 2018-09-28 2020-04-02 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
AU2019352635B2 (en) 2018-10-02 2024-12-19 WearOptimo Pty Ltd Actuator system
JP7379505B2 (ja) 2018-10-02 2023-11-14 ウェアオプティモ ピーティーワイ リミテッド 流体レベルの判定
WO2020230108A1 (en) 2019-05-16 2020-11-19 Aptatargets, S.L. Treatment of ischemic stroke with aptamers targeting tlr-4
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
US20230372407A1 (en) * 2020-06-15 2023-11-23 President And Fellows Of Harvard College Methods for modulating tlr4 signaling
CN114152599B (zh) * 2021-12-01 2023-10-13 中国农业大学 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器
CN114836425A (zh) * 2022-02-25 2022-08-02 温州医科大学附属眼视光医院 检测小胶质细胞的核酸适体及应用
AU2024206573A1 (en) 2023-01-05 2025-08-14 Merck Patent Gmbh Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
WO2024240750A1 (en) 2023-05-22 2024-11-28 Aptatargets, S.L. New tlr-4 antagonist aptamers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US20010046674A1 (en) * 2000-02-03 2001-11-29 Andrew Ellington Signaling aptamers that transduce molecular recognition to a differential signal
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
CN101227922A (zh) * 2005-05-06 2008-07-23 斯克里普斯研究学院 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
WO2008076804A2 (en) * 2006-12-13 2008-06-26 Case Western Reserve University Method of treating intrauterine inflammation
US20100111936A1 (en) * 2008-11-04 2010-05-06 Idera Pharmaceuticals, Inc. Modulation of Toll-Like Receptor 4 Expression by Antisense Oligonucleotides
WO2010060030A1 (en) 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same
WO2012118911A1 (en) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
CN103492572A (zh) * 2011-03-03 2014-01-01 夸克医药公司 用于治疗肺疾病和损伤的组合物和方法
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos

Also Published As

Publication number Publication date
RU2709718C2 (ru) 2019-12-19
RU2016152094A (ru) 2018-07-26
DK3161139T3 (da) 2020-10-19
MA40283A (fr) 2017-05-03
EP3161139A1 (en) 2017-05-03
JP2017527260A (ja) 2017-09-21
BR112016030172A2 (pt) 2017-11-14
AU2015279248A1 (en) 2017-01-12
BR112016030172B1 (pt) 2022-11-01
US10808252B2 (en) 2020-10-20
AU2015279248B2 (en) 2021-03-11
CA2953020A1 (en) 2015-12-30
US11591603B2 (en) 2023-02-28
PL3161139T3 (pl) 2021-01-11
US20230279402A1 (en) 2023-09-07
CN106459980B (zh) 2020-11-03
ES2825106T3 (es) 2021-05-14
SI3161139T1 (sl) 2020-12-31
CA2953020C (en) 2023-01-10
WO2015197706A1 (en) 2015-12-30
PT3161139T (pt) 2020-10-23
KR20170021298A (ko) 2017-02-27
RU2709718C9 (ru) 2020-02-06
CN106459980A (zh) 2017-02-22
US20190211334A1 (en) 2019-07-11
JP2020127422A (ja) 2020-08-27
EP3161139B1 (en) 2020-07-22
JP6959738B2 (ja) 2021-11-05
ES2555160B1 (es) 2016-10-25
US20210130830A1 (en) 2021-05-06
KR102454682B1 (ko) 2022-10-13
US10196642B2 (en) 2019-02-05
MX2016016992A (es) 2017-05-03
RU2016152094A3 (es) 2019-01-29
ES2555160A1 (es) 2015-12-29
US20170130227A1 (en) 2017-05-11
CN112111495A (zh) 2020-12-22
ZA201700363B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
MX387405B (es) Aptámeros específicos de tlr-4 y usos de los mismos.
HUE051476T2 (hu) Kannabidiolsav alkalmazása az epilepszia kezelésében
HRP20190026T1 (hr) Testovi za određivanje prisutnosti ili količine protutijela protiv lijeka
PT3159409T (pt) Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
PT3118311T (pt) Ácido nucleico anti-sentido
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
DK2929031T3 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
EP3329400A4 (en) DISAMBING OF SEARCH QUESTIONS
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
EP3397379A4 (en) PREPARATION OF POTTED PARTICLE PCR BASED LIBRARY
CL2015003672A1 (es) Fabricación de composición explosiva y plataforma de entrega, y métodos explosivos
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
UY35747A (es) Derivados sustituidos de fenilalanina
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112017009289A2 (pt) métodos de administrar composições de amantadina
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
EA201600288A1 (ru) Замещенные фенилаланиновые производные